ATE515505T1 - Heterocyclische fxr-bindende verbindungen - Google Patents

Heterocyclische fxr-bindende verbindungen

Info

Publication number
ATE515505T1
ATE515505T1 AT07801977T AT07801977T ATE515505T1 AT E515505 T1 ATE515505 T1 AT E515505T1 AT 07801977 T AT07801977 T AT 07801977T AT 07801977 T AT07801977 T AT 07801977T AT E515505 T1 ATE515505 T1 AT E515505T1
Authority
AT
Austria
Prior art keywords
compounds
binding compounds
fxr binding
heterocyclic
fxr
Prior art date
Application number
AT07801977T
Other languages
English (en)
Inventor
Claus Kremoser
Ulrich Deuschle
Ulrich Abel
Andreas Schulz
Original Assignee
Phenex Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex Pharmaceuticals Ag filed Critical Phenex Pharmaceuticals Ag
Application granted granted Critical
Publication of ATE515505T1 publication Critical patent/ATE515505T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07801977T 2006-08-29 2007-08-29 Heterocyclische fxr-bindende verbindungen ATE515505T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84091206P 2006-08-29 2006-08-29
EP06018024A EP1894928A1 (de) 2006-08-29 2006-08-29 Fxr bindende heterocyclische verbindungen
PCT/EP2007/007556 WO2008025539A1 (en) 2006-08-29 2007-08-29 Heterocyclic fxr binding compounds

Publications (1)

Publication Number Publication Date
ATE515505T1 true ATE515505T1 (de) 2011-07-15

Family

ID=37663275

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07801977T ATE515505T1 (de) 2006-08-29 2007-08-29 Heterocyclische fxr-bindende verbindungen

Country Status (4)

Country Link
US (1) US8193192B2 (de)
EP (2) EP1894928A1 (de)
AT (1) ATE515505T1 (de)
WO (1) WO2008025539A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7902201B2 (en) 2007-12-04 2011-03-08 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
WO2009071464A1 (en) 2007-12-04 2009-06-11 F. Hoffmann-La Roche Ag Isoxazolo-pyrazine derivatives
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
EP2128158A1 (de) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclische Cyclopropyl-substituierte FXR-bindende Verbindungen
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US8227461B2 (en) 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
MX2011011490A (es) 2009-05-05 2011-11-18 Hoffmann La Roche Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
WO2010127976A1 (en) 2009-05-05 2010-11-11 F. Hoffmann-La Roche Ag Isoxazole-pyridine derivatives
EP2427458B1 (de) * 2009-05-05 2014-05-07 F.Hoffmann-La Roche Ag Isoxazol-Pyridazin-Derivate
AU2010244552A1 (en) 2009-05-05 2011-09-29 F. Hoffmann-La Roche Ag Isoxazole-pyrazole derivatives
MX2011011484A (es) * 2009-05-07 2011-11-18 Hoffmann La Roche Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico.
EP2289883A1 (de) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Neue Aktivitätsmodulationsverbindungen für FXR- (NR1H4)
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
JP2013531030A (ja) * 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
CA2804351A1 (en) * 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
EP2545964A1 (de) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
US9475797B2 (en) 2012-06-26 2016-10-25 Saniona A/S Phenyl triazole derivative and its use for modulating the GABAA receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
CA2876778A1 (en) 2012-06-26 2014-01-03 Saniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
SI3043865T1 (sl) 2013-09-11 2021-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
MX2017003933A (es) 2014-09-24 2017-06-30 Gilead Sciences Inc Metodos de tratamiento de la enfermedad hepatica.
EP3006939A1 (de) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidinreiches Glycoprotein als Marker zur hepatischen Farnesoid-X-Aktivierung
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034499A1 (de) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Neuartige FXR (NR1H4) modulierende Verbindungen
EP3034501A1 (de) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxyhaltige FXR (NR1H4) modulierende Verbindungen
EA036404B1 (ru) 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CA2981503C (en) 2015-03-31 2023-09-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CR20170456A (es) 2015-04-07 2018-06-13 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapias combinadas
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CA2968836C (en) * 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
KR102079844B1 (ko) 2016-09-20 2020-02-20 가톨릭대학교 산학협력단 담석 용해제를 포함하는 담낭 질환 치료용 약학 조성물
MX2019003790A (es) 2016-10-04 2019-09-26 Enanta Pharm Inc Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
WO2018082596A1 (en) 2016-11-03 2018-05-11 Sunshine Lake Pharma Co., Ltd. Solid forms of an adamantyl compound, compositions and uses thereof
JP7618384B2 (ja) 2017-02-21 2025-01-21 ジェンフィ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
SI4122464T1 (sl) 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
WO2018178260A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
MX394743B (es) 2017-04-12 2025-03-04 Il Dong Pharma Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos
CN111278817B (zh) 2017-11-01 2023-05-16 百时美施贵宝公司 作为法尼醇x受体调节剂的多环化合物
JP7264906B2 (ja) 2017-11-01 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
CN111630051B (zh) 2017-11-01 2023-12-26 百时美施贵宝公司 作为法尼醇x受体调节剂的烯烃螺环化合物
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
PT3911647T (pt) 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
EP3972695A1 (de) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituierte exo-methylen-oxindole als hpk1/map4k1-inhibitoren
SG11202113155XA (en) 2019-05-30 2021-12-30 Intercept Pharmaceuticals Inc Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
EP3999101A1 (de) 2019-07-18 2022-05-25 ENYO Pharma Verfahren zur verringerung von störeffekten von interferon
WO2021108974A1 (en) 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Compounds for modulating activity of fxr and uses thereof
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN114315815B (zh) * 2020-10-12 2024-07-19 甘莱制药有限公司 用于调节fxr活性的化合物及其应用
KR20230154806A (ko) 2021-01-14 2023-11-09 엔요 파마 Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
CN115925584A (zh) * 2021-08-27 2023-04-07 广东东阳光药业有限公司 一种取代的金刚烷胺类化合物的结晶方法
CN114807224B (zh) * 2022-04-25 2023-09-29 中国人民解放军军事科学院军事医学研究院 一种可视化斑马鱼胆汁酸代谢模型的构建方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4219247A1 (de) * 1992-06-12 1993-12-16 Bayer Ag Verwendung von 3-arylsubstituierten 5-Alkyl-isoxazol-4-carbonsäurederivaten zur Bekämpfung von Endoparasiten, neue 3-arylsubstituierte 5-Alkyl-isoxazol-4-carbonsäurederivate und Verfahren zu ihrer Herstellung
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
SK174699A3 (en) 1997-06-19 2000-08-14 Du Pont Pharm Co Inhibitors of factor xa with a neutral p1 specificity group
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
ATE381542T1 (de) * 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
JP2006515838A (ja) * 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
CA2564355C (en) * 2004-05-07 2012-07-03 Amgen Inc. Protein kinase modulators and method of use
US8106077B2 (en) 2006-05-24 2012-01-31 Eli Lilly And Company Compounds and methods for modulating FXR

Also Published As

Publication number Publication date
WO2008025539A1 (en) 2008-03-06
EP1894928A1 (de) 2008-03-05
US8193192B2 (en) 2012-06-05
EP2066663A1 (de) 2009-06-10
EP2066663B1 (de) 2011-07-06
US20100210660A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
ATE515505T1 (de) Heterocyclische fxr-bindende verbindungen
ATE555105T1 (de) Heterocyclische fxr-bindende verbindungen
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
BR122019017036B8 (pt) compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
MY173930A (en) Crystalline solvates and complexes of (is)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
TW200800997A (en) Chemical compounds
IN2012DN00790A (de)
HRP20090235B1 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d
TW200628154A (en) Organic compounds
NO20055688L (no) Organiske forbindelser
NO20092689L (no) Quinuclidinolderivater som muskarin reseptorantagonister
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
BRPI0519292A2 (pt) compostos orgÂnicos
EA201001645A1 (ru) Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
EA200601295A1 (ru) Производные 1,3-диоксана и их аналоги, применимые для лечения i.a. ожирения и диабета

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties